On August 24, 2022, the U.S. Food and Drug Administration (FDA) approved ibrutinib for the treatment of pediatric patients older than 1 year with chronic graft-versus-host disease ( cGVHD ) who are receiving After failure of 1- or multi-line systemic therapy . The approved indication is mainly for pediatric patients, with an overall response rate of 60% at week 25, and the drug formulations include capsules, tablets and oral suspensions.

Ibrutinib , a BTK inhibitor co-developed by Pharmacyclics/Johnson & Johnson, is a kinase inhibitor previously approved for the treatment of chronic lymphocytic leukemia as well as cell lymphoma and other diseases .

Suntech focuses on the development and production of pharmaceutical intermediates and APIs using green technology. At present, our company has developed three intermediate products of ibrutinib including C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , all of which have been commercialized in GMP factories production. Among them, the intermediate of C AS: 143900-44-1 is produced by chemical-enzymatic technology , which has the advantages of green environmental protection, low price and high quality. Welcome to consult and cooperate!